US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    Diamyd Medical orders additional Diamyd® drug substance from Protein Sciences

    Diamyd Medical orders additional recombinant GAD-protein, the clinical grade drug substance which is the main component in the diabetes vaccine Diamyd® from its CRO, Protein Sciences Corporation, Connecticut. The order is placed to ensure access to drug substance for future clinical trials, possible early market launch and other opportunities. The order totals approximately USD 750,000 (approximately MSEK 6.1) for which Protein Sciences receives a cash installment and on delivery a payment either through Diamyd Medical series B shares or cash, as then decided by Diamyd Medical.“Diamyd® may

    Publication of change in the total number of shares and votes in Diamyd Medical AB

    As of December 2, 2014, the share capital in Diamyd Medical AB (publ) is 2,010,142.3 SEK. The total number of votes is 2,844,668 and the total number of shares is 19,819,422, divided among 958,584 shares of series A   (1 vote) and 18,860,838 shares of series B (1/10 vote). The change is, as previously announced, due to a direct placement of 100,000 new series B shares to Protein Sciences Corporation, Inc., due to a signed agreement. The Board of Diamyd Medical decided on the new issue based on the authorization given by the Annual General Meeting on November 22, 2013. About Diamyd

    Diamyd Medical and Protein Sciences deepen commitment to develop new treatment for diabetes

    Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) and Protein Sciences Corporation announced today that Protein Sciences has broadened its commitment to diabetes and become a strategic and significant shareholder in Diamyd Medical, its long-time partner in this domain. Protein Sciences will manufacture product for upcoming late stage clinical trials for type 1 diabetes involving Diamyd Medical’s recombinant GAD (glutamic acid decarboxylase) protein made using Protein Sciences’ proprietary Baculovirus Expression Vector System (BEVS) technology. The diabetes vaccine Diamyd® (GAD

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media